article thumbnail

Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

STAT

But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.    The data, presented this week as an abstract at Digestive Disease Week in D.C.,

Labelling 338
article thumbnail

STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure

STAT

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment. of those who received placebo. Continue to STAT+ to read the full story…

Labelling 299
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT

Consequently, such “LDTs” can be quickly brought to market without the FDA review of their effectiveness, labeling accuracy, and marketing claims required for regular tests. Read the rest…

Labelling 331
article thumbnail

AHA 2024: Lerodalciep provides promising results in open-label extension trial, LIBERATE-OLE

Pharmaceutical Technology

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalciep.

article thumbnail

AYUSH, PHD Chamber of Commerce and Industry organise conference on labelling and packaging provisions for ASU products

Express Pharma

AYUSH Committee, PHD Chamber of Commerce and Industry organised a Conference on Labelling and Packaging Provisions for ASU products recently at PHD House, New Delhi. He further urged bigger Industry players to kindly create awareness about the labelling and packaging procedures.

article thumbnail

Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar

Big Molecule Watch

On October 22, 2024, Alvotech and Teva announced that SELARSDI (ustekinumab-aekn) received FDA approval for a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. We previously reported that SELARSDI was approved by the FDA for 45 mg/0.5 launch of SELARSDI approaches in early 2025.”

article thumbnail

Thinking outside of the box: Digitising pharmacy dispensing labels

Pharmaceutical Technology

Written Medicine is a digital solution that provides bilingual dispensing labels, described in a presentation at the NHS ConfedExpo conference in Manchester.